Which Is Better: Semaglutide, Tirzepatide, or Retatrutide?

There is no single best choice for everyone: semaglutide and tirzepatide are both FDA-approved for chronic weight management and type 2 diabetes in the United States, while retatrutide is still an investigational drug that no regulator has approved for human use. Across trials, tirzepatide produces somewhat more average weight loss than semaglutide, and early retatrutide data suggest larger average reductions still, but retatrutide's long-term safety profile is not yet established.

How the Three Drugs Compare at a Glance

All three are injectable incretin-based medications, but they do not hit the same receptors. That difference in receptor activity is the main reason their results differ.

Drug	FDA status	Receptors targeted	Common brand names	Average weight loss in trials
Semaglutide	Approved for diabetes and weight management	GLP-1	Wegovy, Ozempic, Rybelsus	About 15% of body weight (STEP 1, 2.4 mg, 68 weeks)
Tirzepatide	Approved for diabetes and weight management	GIP and GLP-1	Zepbound, Mounjaro	About 21% of body weight (SURMOUNT-1, 15 mg, 72 weeks)
Retatrutide	Investigational, not approved	GIP, GLP-1, and glucagon	None on the market	About 24% of body weight (phase 2, 12 mg, 48 weeks)

Those percentages are averages from specific trials at specific doses. Individual results vary widely, and a person who responds strongly to semaglutide may lose more than a person who responds poorly to tirzepatide.

Tirzepatide vs Semaglutide for Weight Loss

In SURMOUNT-1, participants taking tirzepatide 15 mg lost about 21% of their body weight on average over 72 weeks. In STEP 1, participants taking semaglutide 2.4 mg lost about 15% on average over 68 weeks.

Those two trials were not run head-to-head, so early comparisons were indirect. A later head-to-head trial in adults with obesity without diabetes found greater average weight loss with tirzepatide than with semaglutide.

People searching tirzepatide vs semaglutide which is better for weight loss usually want one number to settle the question. A more useful framing is that tirzepatide is linked to greater average weight loss, while semaglutide has a longer track record, more cardiovascular outcome data, and often a lower monthly cost through insurance.

Tirzepatide vs Semaglutide Side Effects

Both drugs share a similar side effect profile because both activate the GLP-1 receptor. Most complaints are gastrointestinal and are strongest during dose escalation.

• Nausea, the most common complaint for both drugs.
• Diarrhea, constipation, and vomiting.
• Reflux, burping, and feeling full very quickly.
• Injection-site reactions such as redness or mild pain.

Reported rates of nausea and vomiting have been in a similar range for the two approved drugs, and some pooled analyses suggest slightly better tolerability with tirzepatide at comparable weight loss. Tirzepatide is not FDA-approved for human use in any other form, and neither drug should be started without medical supervision.

Serious but uncommon risks for both include pancreatitis, gallbladder disease, bowel obstruction, and low blood sugar when combined with insulin or sulfonylureas. These medications are not used during pregnancy, and they are contraindicated for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome.

Dosing: A Tirzepatide vs Semaglutide Dosage Chart

Drug	Starting dose	Titration	Typical maintenance	Maximum dose
Semaglutide (Wegovy)	0.25 mg weekly	Increase every 4 weeks	1.7 to 2.4 mg weekly	2.4 mg weekly
Tirzepatide (Zepbound)	2.5 mg weekly	Increase every 4 weeks	5 to 15 mg weekly	15 mg weekly
Retatrutide	Not established	Not established	Investigational only	Not established

Neither drug works well when the dose is raised faster than the body tolerates. Skipping titration steps is one of the most common reasons people stop treatment early.

Retatrutide: How Is It Different?

Retatrutide is a triple agonist, meaning it activates GIP, GLP-1, and glucagon receptors. The added glucagon activity is thought to increase energy expenditure, which may explain why phase 2 results showed roughly 24% average weight loss at 48 weeks on the 12 mg dose.

Retatrutide is not approved, is not legally available by prescription, and can only be obtained through clinical trials. Products sold online as retatrutide are unregulated and may contain no active ingredient, the wrong amount, or contaminants.

The question of retatrutide vs tirzepatide which is better cannot be answered yet, because no completed head-to-head trial exists and retatrutide's phase 3 safety data are still pending. Other experimental agents are being studied in the same space, and researchers asking is mazdutide better than retatrutide are likewise working from early-phase data rather than finished comparisons.

Compounded Versions, Safety, and Choosing a Path

Compounded semaglutide and tirzepatide became widely available during supply shortages. Compounded drugs are not FDA-approved, and the agency has warned about dosing errors and adverse events linked to compounded incretins.

If you are sorting out what is the difference between semaglutide and tirzepatide compound and the brand-name versions, the practical differences are the source of the active ingredient, the dosing units printed on the label, and the absence of FDA review for the compounded product.

Anyone weighing which is better tirzepatide or semaglutide should bring a full medical history, current medication list, and insurance coverage details to a licensed healthcare professional. A clinician can factor in kidney function, history of pancreatitis, pregnancy plans, and cost before recommending a starting point.

The clearest conclusions from the available evidence are these:

• Tirzepatide is associated with greater average weight loss than semaglutide in the best available comparison.
• Semaglutide remains an effective, well-studied option with more long-term cardiovascular data.
• Retatrutide is not approved for human use and should not be obtained outside a supervised clinical trial.

COMMON QUESTIONS

Frequently Asked Questions

Which is better for weight loss, semaglutide or tirzepatide?

In a head-to-head trial of adults with obesity without diabetes, tirzepatide produced greater average weight loss than semaglutide. Earlier separate trials reported about 21% average weight loss with tirzepatide 15 mg and about 15% with semaglutide 2.4 mg. Individual results vary, and both drugs are FDA-approved for chronic weight management.

Is retatrutide FDA-approved?

No. Retatrutide is an investigational triple agonist and is not approved for any human use in the United States. It is only available to participants in clinical trials. Products marketed online as retatrutide are unregulated and have not been verified for safety, purity, or dose accuracy.

Can you switch from semaglutide to tirzepatide?

Switching is possible with a clinician's guidance, and it is usually done by starting the new drug at its lowest dose rather than converting milligram for milligram. Overlapping the two drugs or self-adjusting doses is not recommended. A healthcare professional can time the change to limit gastrointestinal side effects.